Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 14NIH 7NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Lung Neoplasms 5Adenocarcinoma of Lung 3Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Salivary Gland Neoplasms 1Recurrent Squamous Cell Lung Carcinoma 1Pancreatic Neoplasms 1Neurofibrosarcoma 1Multiple Myeloma 1MET Positive 1Lymphoma, Non-Hodgkin 1Head and Neck Neoplasms 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Brain Neoplasms 1Adenocarcinoma, Bronchiolo-Alveolar 1

Interventions

Radiotherapy 13Temozolomide 12Carmustine 5Chemotherapy, Adjuvant 3Radiosurgery 2Radiation 2Immunohistochemistry 2Everolimus 2Bevacizumab 2veliparib 1vatalanib 1sagopilone 1rubitecan 1mercaptoundecahydrododecaborate 1lonafarnib 1imetelstat 1beta-D-glucosylisophosphoramide mustard 1azurin (50-77) 1Tamoxifen 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Proton Therapy 1Perfusion Magnetic Resonance Imaging 1O(6)-benzylguanine 1Microarray Analysis 1Methotrexate 1Lomustine 1Leucovorin 1Irinotecan 1In Situ Hybridization, Fluorescence 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Gliosarcoma × Erlotinib Hydrochloride × Clear all
NCT00086879 2017-07-27

Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
110 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡